1. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (26th April 2018) Authors: Loibl, S; Majewski, I; Guarneri, V; Nekljudova, V; Holmes, E; Bria, E; Denkert, C; Schem, C; Sotiriou, C; Loi, S; Untch, M; Conte, P; Bernards, R; Piccart, M; von Minckwitz, G; Baselga, J Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗